0000950170-23-053818.txt : 20231017
0000950170-23-053818.hdr.sgml : 20231017
20231017175104
ACCESSION NUMBER: 0000950170-23-053818
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20231013
FILED AS OF DATE: 20231017
DATE AS OF CHANGE: 20231017
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Kulkarni Samarth
CENTRAL INDEX KEY: 0001682019
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37923
FILM NUMBER: 231330503
MAIL ADDRESS:
STREET 1: C/O CRISPR THERAPEUTICS AG
STREET 2: 200 SIDNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: CRISPR Therapeutics AG
CENTRAL INDEX KEY: 0001674416
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 473173478
STATE OF INCORPORATION: V8
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: BAARERSTRASSE 14
CITY: ZUG
STATE: V8
ZIP: CH-6300
BUSINESS PHONE: 6173154600
MAIL ADDRESS:
STREET 1: BAARERSTRASSE 14
CITY: ZUG
STATE: V8
ZIP: CH-6300
4
1
ownership.xml
4
X0508
4
2023-10-13
false
0001674416
CRISPR Therapeutics AG
CRSP
0001682019
Kulkarni Samarth
C/O CRISPR THERAPEUTICS
105 WEST FIRST STREET
BOSTON
MA
02127
true
true
false
false
Chief Executive Officer
false
Stock Option (Right to Buy)
44.31
2023-10-13
4
A
false
52500
0.00
A
2033-10-13
Common Shares
52500
52500
D
Restricted Stock Unit
2023-10-13
4
A
false
25000
0.00
A
Common Shares
25000
25000
D
This option was granted on October 13, 2023 with respect to 52,500 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of November 13, 2023.
Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.
This restricted stock unit award was granted on October 13, 2023 with respect to 25,000 Common Shares, with (i) one third of the shares vesting on October 13, 2024, (ii) one third of the shares vesting on October 13, 2025, and (iii) one third of the shares vesting on October 13, 2026.
/s/ Elizabeth Ryland Waldinger, attorney-in-fact
2023-10-17